Epygenix Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of EPX-100 to Treat Lennox-Gastaut Syndrome
/PRNewswire/ -- Epygenix Therapeutics, Inc. ("Epygenix"), a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy,...
Source: prnewswire.com